High leukocyte count and interleukin-10 predict high on-treatment-platelet- reactivity in patients treated with clopidogrel

Journal of Thrombosis and Thrombolysis

Volumn 33, Issue 4, 2012, Pages 349-354

  Osmancik, Pavel ^a   Paulu, Petra ^a   Tousek, Petr ^a   Kocka, Viktor ^a   Widimsky, Petr ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Anti platelet drug; CD40L; Clopidogrel; Inflammation; Interleukin 10; Leukocyte; Resistance; VerifyNow

Indexed keywords

CD40 LIGAND; CLOPIDOGREL; INTERLEUKIN 10; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; DRUG DERIVATIVE; IL10 PROTEIN, HUMAN; TICLOPIDINE;

AGED; AGING; ANTICOAGULANT THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE MARKER; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OBESITY; ON TREATMENT PLATELET REACTIVITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; AGE; BLOOD; CLINICAL TRIAL; DRUG RESISTANCE; MIDDLE AGED;

AGE FACTORS; AGED; BIOLOGICAL MARKERS; CD40 LIGAND; DIABETES MELLITUS; DRUG RESISTANCE; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-10; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 84865112417     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-011-0659-5     Document Type: Article

References (22)

1. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C et al (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288:2411-2420
2. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P et al (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352:1179-1189
3. Price MJ (2010) The evidence base for platelet function testing in patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv 3(3):277-83; discussion 283
4. Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C et al (2009) Cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12 month follow-up. Circulation 119:237-242
5. Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP et al (2008) Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 29:992-1000
6. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB et al (2009) Association of cytochrome P4502C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302:849-857
7. Karabinos I, Koulouris S, Kranidis A, Pastromas S, Exadaktylos N, Kalofoutis A (2009) Neutrophil count on admission predicts major in-hospital events in patients with a non-ST-segment elevation acute coronary syndrome. Clin Cardiol 32:561-568
8. Ndrepepa G, Braun S, Iijima R, Keta D, Byrne RA, Schulz S et al (2009) Total leucocyte count, but not C-reactive protein, predicts 1 year mortality in patients with acute coronary syndromes treated with percutaneous coronary intervention. Clin Sci (Lond) 116:651-658
9. Varo N, de Lemos JA, Libby P, Morrow DA, Murphy SA, Nuzzo R et al (2003) Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 108:1049-1052
10. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET et al (2010) Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303(8):754-762
11. Patti G, Nusca A, Mangiacapra F, Gatto L, D'Ambrosio A, Di Sciascio G (2008) Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDAPRO (antiplatelet therapy for reduction of MYocardial damage during angioplasty-platelet reactivity predicts outcome) study. J Am Coll Cardiol 52:1128-1133
12. Motovska Z, Widimsky P, Petr R, Bilkova D, Marinov I, Simek S et al (2009) Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking 'paradox'. J Cardiovasc Pharmacol 53:368-372
13. Osmancik P, Jirmar R, Hulikova K, Peroutka Z, Pompachova A, Motovska Z et al (2010) A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction. Catheter Cardiovasc Interv 75(2):158-166
14. Turner SJ, Ketch TR, Gandhi SK, Sane DC (2008) Routine hematologic clinical tests as prognostic markers in patients with acute coronary syndromes. Am Heart J 155:806-816
15. Sabatine MS, Morrow DA, Cannon CP, Murphy SA, Demopoulos LA, DiBattiste PM et al (2002) Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat angina with aggrastat and determine cost of therapy with an invasive or conservative strategy-thrombolysis in myocardial infarction 18 trial) substudy. J Am Coll Cardiol 40:1761-1768
16. Ge H, Zhou Y, Zhao Y, Shi D, Liu Y, Guo Y et al (2010) Relation between clopidogrel resistance and inflammation factor in patients after coronary stenting. Heart 96:A158-A159
17. Yip HK, Youssef AA, Chang LT, Yang CH, Sheu JJ, Chua S et al (2007) Association of interleukin-10 level with increased 30 day mortality in patients with ST-segment elevation acute myocardial infarction undergoing primary coronary intervention. Circ J 71:1086-1091
18. Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Boersma E, Simoons ML et al (2003) Serum level of the anti-inflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation 107:2109-2114
19. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D et al. (2011) Standard-vs. high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305(11):1097-105
20. Ge H, Zhou Y, Liu X, Nie X, Wang Z, Guo Y, et al. (2011) Relationship between plasma inflammatory markers and platelet aggregation in patients with clopidogrel resistance after angioplasty. Angiology
21. Hermann A, Rauch BH, Braun M, Schror K, Weber AA (2001) Platelet CD40 ligand (CD40L) -subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 12:74-82
22. Sambu N, Dent H, Englyst N, Warner TD, Leadbeater P, Roderick P et al (2011) Effect of clopidogrel withdrawal on platelet reactivity and vascular inflammatory biomarkers 1 year after drug-eluting stent implantation: results of the prospective, singlecentre cessation study. Heart 97(20):1661-1667